Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery, characterization, and clinical development of the glucagon-like peptides
Daniel J. Drucker, Joel F. Habener, Jens J. Holst
Journal of Clinical Investigation (2017) Vol. 127, Iss. 12, pp. 4217-4227
Open Access | Times Cited: 325

Showing 1-25 of 325 citing articles:

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2018) Vol. 27, Iss. 4, pp. 740-756
Open Access | Times Cited: 1241
Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
Yi Tan, Zhiguo Zhang, Chao Zheng, et al.
Nature Reviews Cardiology (2020) Vol. 17, Iss. 9, pp. 585-607
Open Access | Times Cited: 554
Advances in oral peptide therapeutics
Daniel J. Drucker
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 4, pp. 277-289
Closed Access | Times Cited: 495
The cell biology of systemic insulin function
Victoria L. Tokarz, Patrick E. MacDonald, Amira Klip
The Journal of Cell Biology (2018) Vol. 217, Iss. 7, pp. 2273-2289
Open Access | Times Cited: 382
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 274
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery, Victoria E R Parker, Michael Stümvoll, et al.
The Lancet (2018) Vol. 391, Iss. 10140, pp. 2607-2618
Closed Access | Times Cited: 268
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016
Pooyan Kazemian, Fatma M. Shebl, Nicole C. McCann, et al.
JAMA Internal Medicine (2019) Vol. 179, Iss. 10, pp. 1376-1376
Open Access | Times Cited: 221
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
Brent A. McLean, Chi Kin Wong, Jonathan E. Campbell, et al.
Endocrine Reviews (2020) Vol. 42, Iss. 2, pp. 101-132
Open Access | Times Cited: 196
Glucagon Receptor Signaling and Glucagon Resistance
Lina Janah, Sasha A. S. Kjeldsen, Katrine D. Galsgaard, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 13, pp. 3314-3314
Open Access | Times Cited: 156
Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease
Jong Sung Park, Tae‐In Kam, Saebom Lee, et al.
Acta Neuropathologica Communications (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 131
Receptor-associated independent cAMP nanodomains mediate spatiotemporal specificity of GPCR signaling
Selma E. Anton, Charlotte Kayser, Isabella Maiellaro, et al.
Cell (2022) Vol. 185, Iss. 7, pp. 1130-1142.e11
Open Access | Times Cited: 130
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 127
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Aditi R. Saxena, Donal Gorman, Ryan M. Esquejo, et al.
Nature Medicine (2021) Vol. 27, Iss. 6, pp. 1079-1087
Closed Access | Times Cited: 104
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 93
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J. Aronne, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2058-2072
Closed Access | Times Cited: 89
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
Aditi R. Saxena, Juan P. Frías, Lisa Brown, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314493-e2314493
Open Access | Times Cited: 81
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 76
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 70
Human trials exploring anti-aging medicines
Leonard Guarente, David Sinclair, Guido Kroemer
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 354-376
Open Access | Times Cited: 69
Heart–gut microbiota communication determines the severity of cardiac injury after myocardial ischaemia/reperfusion
Jinxuan Zhao, Zhang Qi, Wei Cheng, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 6, pp. 1390-1402
Open Access | Times Cited: 59
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 57
Glucagon‐like peptide agonists: A prospective review
Zamara Mariam, Sarfaraz K. Niazi
Endocrinology Diabetes & Metabolism (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 49
Hepatic glucose metabolism in the steatotic liver
Egeria Scoditti, Silvia Sabatini, Fabrizia Carli, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 5, pp. 319-334
Closed Access | Times Cited: 32
Page 1 - Next Page

Scroll to top